EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy

Min-Hsuan Lin, Pramila Maniam, Dongsheng Li, Bing Tang, Cameron R Bishop, Andreas Suhrbier, Lucy Wales- Earl, Yaman Tayyar, Nigel A J McMillan, Li Li, David Harrich

Molecular Therapy Nucleic Acids · 2025-03 · 36 (1) · 102424

DOI: 10.1016/j.omtn.2024.102424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy Nucleic Acids, 2025-03. Verfasst von Min-Hsuan Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Program of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, no approved antiviral drugs target dengue virus (DENV) infection, leaving treatment reliant on supportive care. DENV vaccine efficacy varies depending on the vaccine type, the circulating serotype, and vaccine coverage. We investigated defective interfering particles (DIPs) and lipid nanoparticles (LNPs) to deliver DI290, an anti-DENV DI RNA. Both DIPs and DI290-loaded LNPs (LNP-290) effectively suppressed DENV infection in human primary monocyte-derived macrophages (MDMs), THP-1 macrophages, and fibroblasts-natural DENV targets. Inhibiting interferon (IFN) signaling with a Janus kinase 1/2 inhibitor or an IFN-α/β receptor 1 (IFNAR1)-binding antibody blocked DIP and LNP-290 antiviral activity. LNP-290 demonstrated a greater than log10 inhibition of DENV viral loads in IFNAR-deficient (Ifnar -/- ) and IFN regulatory factor (IRF) 3 and 7 double knockout (Irf3/7 -/- ) mice. Pathway analysis of RNA sequencing data from LNP-treated C57BL/6J mice, Ifnar -/- mice, and human MDMs treated with LNPs or DENV DIPs indicated DI290 treatment enhanced IFN responses, suggesting IFN-λ and IFN-γ provided antiviral activity when IFN-α/β responses were diminished. While viral interference by DI290 is possible, results did not support RNA replication competition as an inhibition mechanism. These findings suggest that DI290 may be a promising DENV therapeutic by activating the innate immune system.

Schlagwörter

Stichwörter der Autor:innen

DIPsLNPsMT: Delivery StrategiesRNAantiviraldefectivedengueinterferingmousetherapeutic

Autor:innen und Institutionen

  • Program of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
  • Global Virus Network (GVN) Center of Excellence, Australian Infectious Disease Research Centre, Brisbane, QLD 4072, Australia.
  • Menzies Health Institute Queensland and School of Pharmacy and Medical Science, Griffith University, Gold Coast, QLD 4222, Australia.
  • Prorenata Biotech, Molendinar, QLD 4214, Australia.
  • Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, St Lucia, QLD 4072, Australia.

Förderung

  • Wellcome Trust

Zitieren

APA

Lin, M. H., Maniam, P., Li, D., Tang, B., Bishop, C. R., Suhrbier, A., Earl, L. W., Tayyar, Y., McMillan, N. A. J., Li, L., & Harrich, D. (2025). Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy. Molecular Therapy Nucleic Acids, 36(1), 102424. https://doi.org/10.1016/j.omtn.2024.102424

Vancouver

Lin MH, Maniam P, Li D, Tang B, Bishop CR, Suhrbier A, et al. Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy. Molecular Therapy Nucleic Acids. 2025;36(1):102424. doi:10.1016/j.omtn.2024.102424

BibTeX
@article{Lin2025,
  author = {Lin, Min-Hsuan and Maniam, Pramila and Li, Dongsheng and Tang, Bing and Bishop, Cameron R and Suhrbier, Andreas and Earl, Lucy Wales- and Tayyar, Yaman and McMillan, Nigel A J and Li, Li and Harrich, David},
  title = {Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy},
  journal = {Molecular Therapy Nucleic Acids},
  year = {2025},
  volume = {36},
  number = {1},
  pages = {102424},
  doi = {10.1016/j.omtn.2024.102424}
}
Kostenlos starten →